Effect of Rifampin on the Pharmacokinetics of Apixaban, an Oral Direct Inhibitor of Factor Xa

被引：0
|
作者：
Blisse Vakkalagadda
Charles Frost
Wonkyung Byon
Rebecca A. Boyd
Jessie Wang
Donglu Zhang
Zhigang Yu
Clapton Dias
Andrew Shenker
Frank LaCreta
机构：
[1] Bristol-Myers Squibb Company,Research and Development, Discovery Medicine and Clinical Pharmacology
[2] Pfizer Inc,Global Innovative Pharma Business Clinical Pharmacology
[3] Bristol-Myers Squibb Company,Global Biometric Sciences
[4] Bristol-Myers Squibb Company,Pharmaceutical Candidate Optimization
来源：
American Journal of Cardiovascular Drugs | 2016年 / 16卷
关键词：
Rifampin; Apixaban; Breast Cancer Resistance Protein; Absolute Oral Bioavailability; Single Ascend Dose Study;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：119 / 127
页数：8
相关论文
共 50 条
  • [41] Effects of Food on the Pharmacokinetics of Edoxaban, an Oral Direct Factor Xa Inhibitor, in Healthy Volunteers
    Mendell, Jeanne
    Tachibana, Masaya
    Shi, Minggao
    Kunitada, Satoshi
    JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 51 (05): : 687 - 694
  • [42] Arterial antithrombotic effect of apixaban, a direct factor Xa inhibitor, in combination with aspirin and/or clopidogrel in rabbits
    Wong, Pancras C.
    Watson, Carol A.
    Crain, Earl J.
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2008, 28 (06) : E102 - E102
  • [43] EFFECT OF NAPROXEN ON THE PHARMACOKINETICS AND PHARMACODYNAMICS OF EDOXABAN, AN ORAL FACTOR Xa INHIBITOR.
    Mendell-Harary, J.
    Chen, S.
    Noveck, R. J.
    Lee, F.
    Petrushun, V.
    Shi, M.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 87 : S63 - S63
  • [44] Effects of the oral, direct factor Xa inhibitor apixaban on routine coagulation assays and anti-FXa assays
    Hillarp, A.
    Gustafsson, K. M.
    Faxaelv, L.
    Strandberg, K.
    Baghaei, F.
    Blixter, I. Fagerberg
    Berndtsson, M.
    Lindahl, T. L.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2014, 12 (09) : 1545 - 1553
  • [45] The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement
    Lassen, M. R.
    Davidson, B. L.
    Gallus, A.
    Pineo, G.
    Ansell, J.
    Deitchman, D.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2007, 5 (12) : 2368 - 2375
  • [46] Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban - an oral, direct Factor Xa inhibitor in healthy subjects
    Mueck, W.
    Becka, M.
    Kubitza, D.
    Voith, B.
    Zuehlsdorf, M.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2007, 45 (06) : 335 - 344
  • [47] Evaluation of the direct factor Xa inhibitor apixaban in rat models of thrombosis and hemostasis
    Schumacher, W. A.
    Bostwick, J. S.
    Stewart, A. B.
    Xin, B.
    Wong, P. C.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 : 1001 - 1001
  • [48] Evaluation of the oral direct factor Xa inhibitor - betrixaban
    Palladino, Michael
    Merli, Geno
    Thomson, Lynda
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2013, 22 (11) : 1465 - 1472
  • [49] Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban - an oral, direct Factor Xa inhibitor - Are not affected by aspirin
    Kubitza, Dagmar
    Becka, Michael
    Mueck, Wolfgang
    Zuehlsdorf, Michael
    JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 46 (09): : 981 - 990
  • [50] Pharmacokinetics of BAY 59-7939 - an oral, direct Factor Xa inhibitor - in rats and dogs
    Weinz, C
    Buetehorn, U
    Daehler, HP
    Kohlsdorfer, C
    Pleissi, U
    Sandmann, S
    Schlemmer, KH
    Schwarz, T
    Steinke, W
    XENOBIOTICA, 2005, 35 (09) : 891 - 910
12345